Hepatic Steatosis in Patients with Chronic Viral Hepatitis C Treated with Direct Acting Antivirals

1 Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019;7(4):313-324. Search in Google Scholar

2 Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705–1725. Search in Google Scholar

3 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106–1110. Search in Google Scholar

4 Adinolfi L E, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33(6): 1358–1364. Search in Google Scholar

5 Yu ML, Wang CY, Lee MH, et al. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes. J Formos Med Assoc 2023;122(3):202-220. Search in Google Scholar

6 Best CH, Hartroft WS. Liver damage produced by feeding alcohol or sugar and its prevention by choline. Br Med J 1949; 2: 1002–1006. Search in Google Scholar

7 Zelman S. The liver in obesity. AMA Arch Intern Med 1952; 90: 141–156. Search in Google Scholar

8 Thaler H. The fatty liver and its pathogenetic relation to liver cirrhosis. Virchows Arch Pathol Anat Physiol Klin Med 1962; 335: 180–210. Search in Google Scholar

9 Ludwig J, Viggiano TR, McGill DB et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–438. Search in Google Scholar

10 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–1231. Search in Google Scholar

11 Thomas G, Cotter MR. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease Gastroenterology 2020; 158: 1851–1864. Search in Google Scholar

12 Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Bio-chemical markers of liver fibrosis in patients with hepatitis C virus infection: aprospective study. Lancet 2001; 357(9262): 1069–1075. Search in Google Scholar

13 Poynard T, Lassailly G, Diaz E et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012; 7: 30325. Search in Google Scholar

14 Bedogni G, Bellentani S, Miglioli L et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33. Search in Google Scholar

15 Calori G, Lattuada G, Ragogna F et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145–152. Search in Google Scholar

16 Lee JH, Kim D, Kim HJ et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42: 503–508. Search in Google Scholar

17 Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010; 10: 98. Search in Google Scholar

18 Otgonsuren M, Estep MJ, Hossain N et al. Single noninvasive model to diagnose nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 2014; 29: 2006–2201. Search in Google Scholar

19 Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 2019; 28; 25(40):6053-6062. Search in Google Scholar

20 Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol. 2009; 15(40): 5014–5019. Search in Google Scholar

21 Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000; 33(1): 106–115. Search in Google Scholar

22 Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alphainterferon. J Hepatol. 2001; 35(2):307. Search in Google Scholar

23 Bochud PY, Cai T, Overbeck K et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51(4): 655–666. Search in Google Scholar

24 Meissner EG, Lee YJ, Osinusi A et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015; 61(3): 790–801. Search in Google Scholar

25 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62(1): 47–64. Search in Google Scholar

26 Kralj D, VirovicJukic L, Stojsavljevic S, Duvnjak M, Smolic M, Curcic IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Translational Hepatol 2016; 4(1): 66–75. Search in Google Scholar

27 Seronello S, Ito C, Wakita T, Choi J. Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem 2010; 285(2): 845–854. Search in Google Scholar

28 Trifan A, Stratina E, Rotaru A, et al. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response. Diagnostics (Basel) 2022; 13;12(3):702. Search in Google Scholar